| Name | Title | Contact Details |
|---|
Effector Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby information in genetic sequences is used to direct synthesis of proteins. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses. In cancer, the tightly controlled translation of specific proteins becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastases. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.
Prolong is dedicated to the global biotechnology market, and to developing relationships with companies worldwide for raw material supply, commercial development and marketing of its new wave of products - the Supergenerics.
With Vytelle, cattle producers increase accuracy of feed intake and bodyweight measurement, improve certainty of genetic selection and accelerate progress.
MBL is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.